Showing 1 - 6 results of 6 for search 'Denis Poddubnyy', query time: 0.02s Refine Results
  1. 1
    Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate

    Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spon... by Xenofon Baraliakos, Denis Poddubnyy, Ludwig Hammel, Marvin Heyne, Justyna Veit, Claudia Jentzsch

    Published 2020-09-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Biomarkers reflecting disturbed gut barrier under treatment with TNF inhibitors in radiographic axial spondyloarthritis

    Biomarkers reflecting disturbed gut barrier under treatment with TNF inhibitors in radiographic axial spondyloarthritis by Denis Poddubnyy, Hildrun Haibel, Fabian Proft, Mikhail Protopopov, Valeria Rios Rodriguez, Murat Torgutalp, Judith Rademacher, Laura Spiller, Christine Maria Hempel

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Association between resolution of MRI-detected inflammation and improved clinical outcomes in axial spondyloarthritis under long-term anti-TNF therapy

    Association between resolution of MRI-detected inflammation and improved clinical outcomes in axial spondyloarthritis under long-term anti-TNF therapy by Joachim Sieper, Denis Poddubnyy, Fabian Proft, Mikhail Protopopov, Valeria Rios Rodriguez, Murat Torgutalp, Judith Rademacher, H Haibel, Kay-Geert Hermann, Christian Althoff

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Influence of sacroiliac joint variation on clinical features of axial spondyloarthritis: a comparative analysis

    Influence of sacroiliac joint variation on clinical features of axial spondyloarthritis: a comparative analysis by Denis Poddubnyy, Torsten Diekhoff, Sevtap Tugce Ulas, Fabian Proft, Valeria Rios Rodriguez, Judith Rademacher, Juliane Greese, Katharina Ziegeler, Carolina Dominguez Aleixo, Maximilian Lindholz

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension

    Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and i... by Sofia Ramiro, Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, Denis Poddubnyy, Lianne S Gensler, Helena Marzo-Ortega, Natasha de Peyrecave, Victoria Navarro-Compán, Tetsuya Tomita, Carmen Fleurinck, Ute Massow, Thomas Vaux

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

    Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study by Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Xianwei Bu, Ivan Lagunes-Galindo, In-Ho Song, Peter Wung, Koji Kato, Anna Shmagel

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: